The company has submitted an application to the TGA for registration of twice-yearly lenacapavir for pre-exposure prophylaxis to prevent the acquisition of HIV.
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News -
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 - - Australian Biotech -
PYC Therapeutics to progress polycystic kidney disease trial
July 7, 2025 - - Australian Biotech -
Pharmac minister prepares to deliver letter of expectations
July 7, 2025 - - Latest News -
UK's ten-year plan backs faster access, but industry laments lack of investment
July 7, 2025 - - Latest News